Ascendis Pharma (ASND) reported its fourth-quarter 2024 earnings, highlighting a significant revenue increase and a positive market reaction. The company posted total revenue of €173.9 million for the ...

DOC has undertaken a journey to strengthen its presence in the pharmaceutical market, beginning with expanding its product ...

Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...